March 30 (Reuters) – Royalty Pharma said on Monday it has signed a $500 million research and development agreement with Johnson & Johnson to advance an experimental antibody treatment for autoimmune diseases.
Shares of Royalty Pharma were up 1.4% in premarket trading, while those of J&J rose nearly 0.7%.
(Reporting by Kunal Das in Bengaluru; Editing by Diti Pujara)
Comments